TK-216 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This TK-216 Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 18 September 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Executive recommendation: CONDITIONAL GO
Decision memo
Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.
The central underwriting question is whether TK-216 can convert its Small molecule drug profile and FLI1 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | TK-216 (query alias: TK-216) |
|---|---|
| Modality / target | Small molecule drug; FLI1; Proto-oncogene protein c-fli-1 inhibitors |
| Highest global status | Phase 2 |
| Originator | Oncternal Therapeutics, Inc. |
| Active developers | Shanghai Pharmaceuticals Holding Co., Ltd., Shanghai Pharmaceutical Usa, Inc. |
The MCP disease footprint includes Recurrent Ewing Sarcoma, Ewing Sarcoma. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT05046314 | Phase 2 | Completed | 15 | Primary endpoint not disclosed in English source |
| CTR20211685 | Phase 2 | Completed | 30 | Primary endpoint not disclosed in English source |
| NCT02657005 | Phase 1/2 | Terminated | 85 | Primary endpoint not disclosed in English source |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
Open-Label, Multicenter, Phase I/II, First-in-Human Trial of TK216: A First-Generation EWS::FLI1 Fusion Protein Antagonist in Ewing Sarcoma
Phase 1/2; n=85; evaluation: Negative. Reported fields: MTD = 200 mg/m^2
TK216 for relapsed/refractory Ewing sarcoma: Interim phase 1/2 results.
Phase 1/2; n=67; evaluation: Positive. Reported fields: CBR = 46.4 %
1620O - Phase I study of TK216, a novel anti-ETS agent for Ewing sarcoma
Phase 1; n=32; evaluation: Positive. Reported fields: Anemia = other AEs of anemia
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
TK-216 addresses Recurrent Ewing Sarcoma, Ewing Sarcoma. Commercial attractiveness rests on addressable patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The MCP screen returned 1 matched transaction record(s) under the scope “asset-specific.” Partner activity is a market-validation signal, but it does not establish net present value.
5. Transaction precedent and economics
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2014-03-26 | Exclusive License Agreement between Georgetown University and Oncternal Therapeutics, Inc., dated March 26, 2014 | Preclinical | Financial terms not disclosed |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
The milestone feed surfaced a patent-application signal described as “Uses of indolinone compounds”. The milestone feed surfaced a patent-application signal described as “Indolinone compounds and uses thereof”.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights.
7. Principal risks and diligence gates
- Therapeutic index and off-target toxicity
- Resistance biology and biomarker-defined patient selection
- Differentiation from established and emerging standards
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
CONDITIONAL GO
Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 2026-09-18. Counts and status fields may change as source records update.
